A non-opioid pain medication made by Vertex Pharmaceuticals has received approval for adults from the Food and Drug ...

BMO Capital analyst Evan Seigerman raised the firm’s price target on Vertex Pharmaceuticals (VRTX) to $545 from $520 and keeps an Outperform ...

Despite healthcare sector struggles, Vertex Pharmaceuticals has outperformed both its biotech peers and the broader market since 2022. The company dominates the cystic fibrosis market and is ...

Leerink Partners analyst David Risinger has reiterated their bullish stance on VRTX stock, giving a Buy rating yesterday. David Risinger has given his Buy rating due to a combination of factors ...

By combining Aerospace's deep expertise in space science with Google Cloud's advanced technologies like Vertex AI and high-performance computing, more accurate and timely space weather predictions ...

Reuters, the news and media division of Thomson Reuters, is the world’s largest multimedia news provider, reaching billions of people worldwide every day. Reuters provides business, financial ...

In the latest trading session, Vertex Pharmaceuticals (VRTX) closed at $440.68, marking a -0.72% move from the previous day. Vertex (VRTX) has received quite a bit of attention from Zacks.com ...

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF ...

LOS ANGELES, CA, UNITED STATES, January 24, 2025 /EINPresswire / -- Logos Faith Development LLC (LOGOS), under the leadership of Pastor Martin Porter, is pleased to announce the commitment of $ ...

Frontier Airlines is attempting for a second time to merge with the now bankrupt Spirit Airlines, which declared bankruptcy late last year as budget airlines... U.K. Treasury chief Rachel Reeves ...